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Objectives: Cyclosporine (INN: ciclosporin) A or tacrolimus have been used mostly
in combination with azathioprine as primary immunosuppression after lung trans-
plantation. Benefit or risk deriving from the combination with mycophenolate
mofetil are yet unknown.
Methods: In a prospective, 2-center, open randomized trial, the combination of
cyclosporine A, mycophenolate mofetil, and steroids was compared with tacrolimus,
mycophenolate mofetil, and steroids as primary therapy after primary lung transplan-
tation. All patients underwent induction therapy with rabbit antithymocyte globulin
for 3 days. The 2 groups were compared with regard to patient survival, freedom
from acute rejection, bronchiolitis obliterans, infectious episodes, and side effects.
Results: Between September 1997 and April 1999, 74 lung transplant recipients
were randomized to receive either cyclosporine A (n  37) or tacrolimus (n  37).
Groups were comparable with regard to age, sex, transplant procedure, and cyto-
megalovirus match. Mean follow-up was 507  258 and 508  248 days, respec-
tively. Six- and 12-month survival was similar in both groups (89% vs 84% and 82%
vs 71%, respectively; P  .748 at 12 months). Two patients from the cyclosporine
A group were retransplanted. Freedom from acute rejection at 6 and 12 months was
comparable between groups (46% vs 51% and 35% vs 46%, respectively; P  .774
at 12 months). The mean number of treated acute rejection episodes per 100
patient-days was higher in the cyclosporine A than in the tacrolimus group, but the
difference was not statistically significant (0.32 0.42 vs 0.22 0.30, respectively;
P  .097). Four patients from the cyclosporine A group had to be switched to
tacrolimus to control ongoing rejection, whereas no patient from the tacrolimus
group had to be switched to cyclosporine A. There was a trend toward more
infections (0.7  0.36 vs 0.55  0.31, P  .059) in the cyclosporine A group.
New-onset diabetes mellitus was observed in the tacrolimus group only (11% vs 0%,
P .151), whereas there was a higher incidence of hypertension (60% vs 11%, P
.03) in the cyclosporine A group.
Conclusion: This 2-center, prospective randomized study showed high immunosup-
pressive potency of both cyclosporine A and tacrolimus in combination with
mycophenolate mofetil. No significant difference in incidence of acute rejection was
observed between the 2 groups. Moreover, survival and incidence of infection were
similar. Incidence of drug-related adverse events were similar, yet their spectrum
was different.
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Although lung transplantation has becomean established therapeutic option for thetreatment of end-stage pulmonary dis-ease, the long-term outcome is still lim-ited by bronchiolitis obliterans (BO). Thefrequency and severity of acute rejection
episodes are the most important risk factors for the subse-
quent development of BO. The standard immunosuppres-
sive regimen, consisting of cyclosporine (INN: ciclosporin)
A (CsA), azathioprine, and prednisolone, is associated with
an unacceptably high incidence of BO. The use of new
immunosuppressive drugs is expected to improve long-term
results after lung transplantation.
Several groups have demonstrated that mycophenolate
mofetil (MMF) decreases the incidence of acute rejection
after lung transplantation.1-3 For this reason, MMF has
replaced azathioprine as standard immunosuppression in
many centers. Lower rates of acute rejection and BO with
the use of tacrolimus have been shown in a prospective
randomized trial by Keenan and colleagues.4 However, only
one study, conducted in a small number of patients, has
investigated the potential beneficial effect of a combination
of tacrolimus and MMF and has reported an even lower rate
of rejection.5
The aim of this 2-center, prospective randomized trial
was to compare the efficacy and safety of a combination of
tacrolimus, MMF, and prednisone versus a combination of
CsA, MMF, and prednisone for prevention of acute rejec-
tion in lung transplantation.
Patients and Methods
Patient Population and Study Design
Seventy-four consecutive adult patients undergoing primary lung
transplantation between September 1997 and April 1999 were
included in the study. Patients were randomized to receive either
CsA (n  37) or tacrolimus (n  37) as part of their maintenance
immunosuppression. Because of the higher risk for infectious
complications, randomization was performed to evenly distribute
patients with cytomegalovirus (CMV) mismatch (donor  recip-
ient), cystic fibrosis, or both among both groups. Formal approval
for the conduct of this study was obtained from local ethics
committees before enrollment, and informed consent was received
from each patient. The trial was performed in accordance with the
Declaration of Helsinki.
Patient demographics are shown in Table 1. There were no
differences between the 2 groups regarding age, sex, type of
procedure, and indication for transplantation.
Mean follow-up was 507  258 days (range, 365-838 days) in
the CsA group and 508  248 days (range, 365-910 days) in the
tacrolimus group.
Immunosuppression
Antithymocyte globulin induction. All patients received rab-
bit antithymocyte globulin (ATG) as induction treatment over the
first 3 days after transplantation (thymoglobulin, 2.5 mg  kg1 
d1; IMTIX-SangStat, Lyon, France).
Cyclosporine A. CsA was started intravenously at a dosage of
1 mg  kd1  d1 immediately after transplantation. Patients were
switched to CsA capsules (Neoral) as early as possible after
extubation. Target levels were between 250 and 350 ng/mL (FPIA)
during the first month and around 200 ng/mL thereafter, depending
on kidney function.
Tacrolimus. Patients in the tacrolimus group were started on
tacrolimus intravenously at a dose of 0.015 mg/kg immediately
after transplantation. Oral tacrolimus was administered at a dosage
of 0.1 to 0.3 mg  kg1  d1 after extubation. Target levels were
between 12 and 15 ng/mL during the first month and between 9
and 12 ng/mL thereafter, depending on kidney function.
Mycophenolate mofetil. MMF was administered at a dosage
of 2 g/d. As long as patients were intubated, MMF was adminis-
tered through a nasogastric tube and orally after extubation. Drug
dose was reduced, or the drug was temporarily discontinued when-
ever adverse events (leukopenia and nausea) occurred.
Steroids. Methylprednisolone (500-1000 mg administered in-
travenously) was given before opening of the pulmonary arterial
clamp. During the first 24 hours after transplantation, patients
received 3 further doses of methylprednisolone (125 mg). On the
first postoperative day, prednisone was started at 1 mg/kg and
tapered to 0.5 mg/kg during the first week after transplantation.
Prednisone was further tapered to 0.15 to 0.2 mg/kg within the first
3 months after transplantation.
TABLE 1. Comparison of CsA/MMF/steroids versus tacroli-
mus/MMF/steroids after lung transplantations: Demograph-
ics
CsA Tacrolimus P value
Age (y)
Mean  SEM 46 13 50 10 .808
Range 20-66 24-65 NS
Sex (male/female) 15/22 22/15 .495
Underlying disease
Emphysema 15 (41%) 22 (59%) .495
Restrictive disease* 14 (38%) 10 (27%) .635
Vascular disease† 5 (13%) 2 (6%) .491
Cystic fibrosis 3 (8%) 3 (8%) .671
Type of transplant procedure
SLTX3 12 (32%) 16 (43%) .673
BLTX4 25 (68%) 21 (57%) .783
CMV D/R‡ 9 (24%) 8 (24%) .960
SLTX, Unilateral lung transplantation; BLTX, sequential bilateral lung trans-
plantation.
*Restrictive disease: CsA group, idiopathic pulmonary fibrosis (n 12), BO
(n  1), lymphangioleiomyomatosis (n  1); tacrolimus group, idiopathic
pulmonary fibrosis (n  9), sarcoidosis (n  1).
†Vascular disease : CsA group, primary pulmonary hypertension (n  3),
Eisenmenger disease (n  2); tacrolimus group, primary pulmonary hyper-
tension (n  2).
‡CMV mismatch, An organ from a donor positive for CMV was transplanted
into a recipient negative for CMV. Brackets contain percentages of the
total number of patients in either of the study groups.
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Diagnosis and Treatment of Rejection
Diagnosis of acute allograft rejection was made on the basis of
clinical (dyspnea, weakness, low-grade fever, and malaise), spiro-
metric (sudden significant decrease in forced expiratory volume in
1 second, mean maximal expiratory flow, or both), and radiologic
(perihilar or diffuse alveolar infiltrates) criteria when infection
could be ruled out as a cause for these symptoms. Efforts were
made to obtain transbronchial biopsy specimens for histologic
diagnosis whenever a rejection episode was suspected. Surveil-
lance transbronchial biopsies were performed at 3 weeks and at 3,
6, and 12 months after transplantation and graded according to the
guidelines of the International Society for Heart and Lung Trans-
plantation.6,7
Treatment of acute rejection was initiated if clinical, spiromet-
ric, or radiologic signs or symptoms were present (irrespective of
histologic grade) or if histologic examination revealed acute re-
jection of grade A2 or higher (irrespective of clinical findings).
Acute rejection episodes were treated with 500 to 1000 mg of
intravenous methylprednisolone for 3 consecutive days, followed
by an oral taper of steroids. The primary choice for treatment of
ongoing or recurrent rejection was a switch from one study drug to
another (CsA to tacrolimus or tacrolimus to CsA). If rejection
persisted after a switch, a 10-day course of OKT3 (5 mg/d) was
initiated.
Infectious Prophylaxis
Antibacterial prophylaxis consisted of piperacillin-tazobactam (4.5
g administered intravenously 3 times per day) for 10 days after
transplantation. In case of positive bacterial cultures, antibiotic
therapy was adjusted according to sensitivity tests. Antifungal
prophylaxis consisted of aerosolized amphotericin B, which was
administered until surveillance bronchoscopy demonstrated com-
plete healing of the bronchial anastomosis. All patients received
antiviral prophylaxis consisting of 10 mg  kg1  d1 ganciclovir
administered intravenously for 3 weeks, followed by 3 g/d orally
until postoperative day 90. Additionally, patients received a course
of anti-CMV hyperimmunoglobulin (Cytotect, 100 mL; Biotest,
Dreireich, Germany) administered at days 1, 7, 14, 21, and 28 after
transplantation. All patients received lifelong prophylaxis against
Pneumocystis carinii and Toxoplasma gondi (trimetoprim-sulfa-
methoxazol 3 times per week).
Infectious Diagnosis and Treatment
Bacterial and fungal cultures were taken from donor and recipient
bronchus. During any hospitalization, bacterial and fungal cultures
were obtained from blood, urine, and sputum on a weekly basis, as
well as from every bronchoalveolar lavage fluid specimen. CMV
screening was performed by means of weekly measurement of
CMV serology and detection of CMV early antigen in blood,
urine, throat wash, and bronchoalveolar lavage fluid. Bacterial and
fungal cultures, as well as polymerase chain reactions, for Toxo-
plasma gondii and Pneumocystis carinii were performed with each
bronchoalveolar lavage. In addition, transbronchial biopsy speci-
mens were histologically screened for CMV, bacterial, or invasive
fungal infection.
Figure 1. Kaplan-Meier estimated survival for patients with tacrolimus (TRL) or cyclosporine (CsA). Numbers of
patients at risk are shown along the curves.
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Bacterial and fungal infection was diagnosed, and treatment
was initiated in the early postoperative phase when cultures were
positive for microorganisms. In stable patients antibacterial and
antifungal treatment was initiated in the eventuality of positive
cultures when clinical symptoms were also present.
Therapy with intravenous ganciclovir was initiated when CMV
early antigen was detected in blood or if CMV syndrome could be
diagnosed and CMV was shed in urine, throat wash, or bronchoal-
veolar lavage fluid.
Bronchiolitis Obliterans Syndrome
BO was defined according to the guidelines of the International
Society for Heart and Lung Transplantation.8
Study End Points
The primary end point of the study was the prevention of acute
allograft rejection expressed as freedom from rejection and inci-
dence of rejection episodes per 100 patient days. Secondary end
points were survival, incidence of infectious episodes, and adverse
events.
Patients were excluded from further analysis if they were
switched from one study drug to the other or had to undergo
retransplantation. Nevertheless, these patients were followed up
and analyzed separately.
Statistical Analysis
Actuarial survival and freedom from rejection were calculated by
using the Kaplan-Meier estimator and compared by means of
log-rank testing. Episodes of rejection and infection were ex-
pressed per 100 patient-days and compared with the unpaired
Student t test. Differences in proportions between the CsA and
tacrolimus groups were calculated by using the 2 test.
Results
Survival
Three-, 6-, and 12-month survivals were 89%, 89%, and
82% in the CsA group compared with 89%, 84%, and 71%
in the tacrolimus group (P  not significant, Figure 1).
Causes of death were septic multiorgan failure (n  4),
bacterial pneumonia (n  2), fungal infection (n  1), and
esophageal carcinoma (n  1) in the CsA group compared
with septic multiorgan failure (n  5), fungal infections
(n  3), intracerebral mass bleeding (n  1), CMV pneu-
monitis (n  1), and tuberculosis (n  1) in the tacrolimus
group, respectively.
Two patients in the CsA group had to have a second
transplant operation 22 and 50 days after the primary pro-
cedure because of unspecific graft failure. One of them died
of bacterial pneumonia 1 month after retransplantation.
Acute Rejection
Freedom from acute rejection at 3, 6, and 12 months after
transplantation was similar in both groups (60%, 46%, and
35% in the CsA group compared with 60%, 51%, and 46%
Figure 2. Kaplan-Meier estimated freedom from acute clinical rejection for patients with tacrolimus (TRL) or
cyclosporine (CsA). Numbers of patients at risk are shown along the curves.
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in the tacrolimus group, respectively; P  .774; Figure
2). The average number of acute rejection episodes per
100 patient-days was similar in both groups (tacrolimus
group: 0.22  0.30 vs CsA group: 0.32  0.42; P  .11;
Figure 3).
Recurrent Acute and Ongoing Rejection
Freedom from recurrent acute rejection episodes was not
different between the 2 groups (CsA group: 87% vs tacroli-
mus group: 84%; P  .967) during the entire follow-up
(Figure 4).
Four patients from the CsA group were switched to
tacrolimus because of recurrent acute rejection episodes
(months 4, 6, 7, and 11); of these, 3 patients survived
without further evidence of acute rejection and without
development of BO. The fourth patient, who was already in
BO syndrome grade IIIb before the switch, died 10 months
later. No patient from the tacrolimus group was switched to
CsA.
Ongoing steroid refractory rejection was diagnosed in 3
patients in the CsA group and in 1 patient in the tacrolimus
group and was treated with OKT3.
Figure 3. Acute clinical rejections per 100 patient-days. Comparison between patients treated with tacrolimus (TRL)
and those treated with cyclosporine (CyA). MMF, Mycophenolate mofetil.
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Bronchiolitis Obliterans
Three patients in each group had BO syndrome during
follow-up (BO syndrome grade IIIb, n  2 in each group;
and BO syndrome grade Ib, n  1 in each group). One
patient in each group had BO syndrome after recurrent acute
rejection episodes. Two other patients (one in each group)
had BO syndrome after late rejections, which were associ-
ated with noncompliance to study medication (Figure 5).
Infections
A trend toward a higher number of overall infection epi-
sodes per 100 patient-days was observed in the CsA group
(CsA, 0.7  0.36; tacrolimus, 0.55  0.31; P  .059).
There was also a trend toward higher rates of bacterial
infections in the CsA group (0.44  0.53) compared with
that in the tacrolimus group (0.25  0.35, P  .089),
whereas incidence of fungal (tacrolimus group: 0.14 0.32
vs CsA group: 0.09  0.27; P  .470) and viral (CsA
group: 0.18  0.29 vs tacrolimus group: 0.16  0.27; P 
.760) infection was comparable between both groups (Fig-
ure 6).
Adverse Events
Adverse events data are shown in Table 2. At 6 and 12
months after transplantation, creatinine levels were
similar in both groups. No patient from the tacrolimus
group had renal insufficiency during intravenous admin-
istration of this drug. The percentage of patients with
renal dysfunction (creatinine, 2.0 mg/dL) increased in
both groups from month 6 to month 12 after transplan-
tation.
The number of patients requiring antihypertensive treat-
ment was significantly higher in the CsA group than in the
tacrolimus group at 6 and 12 months, respectively (P 
.03), whereas the need for statin therapy was similar in both
groups (P  .474).
New onset of diabetes mellitus was observed only in the
tacrolimus group (11% of patients at both 6 and 12 months,
P  .151). Leukopenic events occurred in 7 (19%) patients
in the CsA group compared with 8 (22%) patients (P 
.962) in the tacrolimus group. In case of leukopenic events,
MMF was reduced or discontinued temporarily. Incidence
of gastrointestinal side effects (mostly nausea and diarrhea)
was similar in both groups (CsA, n  6; tacrolimus, n  6).
Two cases of malignant disease (posttransplant lymphopro-
liferative disease, n  1; esophageal carcinoma, n  1)
developed in the CsA group 9 and 17 months after trans-
plantation. No malignancies were observed in the tacroli-
mus group.
Figure 4. Kaplan-Meier estimated freedom from recurrent acute clinical rejection for patients with tacrolimus (TRL)
or cyclosporine (CsA). Numbers of patients at risk are shown along the curves.
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Figure 5. Kaplan-Meier estimated freedom from bronchiolitis obliterans for patients with tacrolimus (TRL) or
cyclosporine (CsA). Numbers of patients at risk are shown along the curves.
Figure 6. Overall, bacterial, viral, and fungal infections per 100 patient-days. Comparison between patients treated
with tacrolimus (TRL) and those treated with cyclosporine (CyA). MMF, Mycophenolate mofetil.
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Discussion
This 2-center, prospective randomized study showed high
immunosuppressive potency of both CsA and tacrolimus in
combination with MMF. No significant difference in the
incidence of acute rejection was observed between the 2
groups, yet there was a trend toward fewer rejections per
100 patient-days in the tacrolimus-MMF group. Survival
and overall incidence of infection were similar. Only overall
drug-related adverse events were different between the 2
groups.
Different protocols with new immunosuppressive drugs
have been shown to decrease the incidence of acute rejec-
tion after lung transplantation. Studies by the Pittsburgh and
Munich groups showed a lower rejection incidence when
tacrolimus was used instead of CsA.1,7 On the other hand,
our group, as well as others, have shown that replacing
azathioprine with MMF in combination with CsA decreased
the incidence of acute rejection.1-3 However, the only re-
ported experience with a combination of tacrolimus and
MMF derives from a small group of 12 patients.7 The
assumption that a combination of tacrolimus and MMF
might have a different immunosuppressive potency than the
combination of CsA and MMF derives from data that sug-
gest a different influence of either tacrolimus or CsA on
mycophenolate acid bioavailability. Studies at our centers
are underway to detect the influence of these calcineurin
inhibitors on mycophenolate acid blood levels.
No significant difference in the incidence of acute rejec-
tion between groups was observed. This observation is in
contrast to a study performed by the Pittsburgh group that
showed significantly lower rejection rates with tacrolimus
compared with CsA. A potential explanation could be the
use of CsA capsules (Neoral) instead of conventional CsA
in our study. Yet it remains speculative whether the immu-
nosuppressive potency of both combinations is equal or
whether a difference did not become obvious only because
of the limitations of this study. Limiting factors might be the
overall small patient number and the study design itself.
Although differences with regard to the type of procedure
(unilateral lung transplantation vs sequential bilateral lung
transplantation) and indications for transplantation were not
significant, larger multi-institutional studies should be strat-
ified for these variables to strengthen results.
A potential limiting factor for the interpretation of data
with regard to acute rejection is the overall small number of
patients. However, an important finding of this trial is the
lower rejection rate in both groups compared with that seen
in studies using tacrolimus or CsA in combination with
azathioprine. Therefore, one could assume that the combi-
nation of either study drug with MMF instead of azathio-
prine is responsible for the lower rejection rate. The overall
lower rate of rejection compared with that seen in other
trials might be due to the use of ATG induction therapy.
This assumption is supported by the results of a European
multicenter tacrolimus heart pilot study, which showed sig-
nificantly fewer rejection episodes in both study groups
(CsA and tacrolimus) when ATG induction therapy was
used compared with episodes in both groups without induc-
tion therapy.9 However, no compelling data from random-
ized trials about the potential effect of ATG induction in
lung transplantation are available thus far.
Acute rejection episodes are the strongest known risk
factor for the development of chronic rejection, pathohisto-
logically defined as BO.10-14 BO, on the other hand, is the
TABLE 2. Adverse events at 6 and 12 months after lung transplantation in patients receiving either CsA/MMF/steroids or
tacrolimus/MMF/steroids
CsA Tacrolimus P value
Creatinine (mg/dL)
6 mo (means  SD) 1.4 0.3 1.4 0.4 1.000
12 mo (means  SD) 1.5 0.4 1.6 0.7 .453
Renal dysfunction (creatinine 2.0)
6 mo 3% 5% .982
12 mo 10% 16% .797
Patients receiving antihypertensive therapy (%)
6 mo 41% 14% .08
12 mo 60% 11% .03
Patients treated for hypercholesterolemia (%)
6 mo 41% 27% .526
12 mo 75% 53% .474
Diabetes mellitus (new onset)
6 mo 0% 11% .151
12 mo 0% 11% .151
Malignancy at 12 mo (%) 5% 0% .497
No. of overall adverse events per patient at
12 mo after transplantation
1.5 0.9 0.9 0.8 .097
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most significant long-term cause of morbidity and mortality
after lung transplantation.
Currently, follow-up of both study groups is too short to
detect an effect on the incidence of BO. However, the low
rejection rates in both groups are promising for long-term
follow-up.
There is some evidence that the immunosuppressive po-
tency of the tacrolimus-MMF combination might be higher
than that of the CsA-MMF combination, probably because
of pharmacokinetic interactions. Our experience with 4 pa-
tients switched from CsA to tacrolimus after recurrent acute
rejection episodes is in accordance with those of others who
showed similar experiences with tacrolimus rescue thera-
py.15-18 During tacrolimus-MMF therapy (after switching),
no acute rejection episodes were observed in these patients.
There is too little knowledge on the long-term outcomes of
such patients, and more studies have to be undertaken to
gain information on the risk/benefit ratio of this therapeutic
option.
Analysis of infectious complications showed a trend
toward more overall and bacterial infections in the CsA
group. Overall incidence of infections was similar to that
reported with other immunosuppressive regimens.1-5 Only
the fact that there were 3 deaths from fungal infection in the
tacrolimus group is worrisome. This points out that perhaps
the combination of tacrolimus and MMF might increase the
risk for severe fungal infections, and intensified prophylaxis
should be warranted.
As expected, the spectrum of side effects was different
according to the calcineurin inhibitor that was used. New
onset of diabetes mellitus was seen only in the tacrolimus
group. All patients had diabetes within the first 6 months
after transplantation, and all of them remained insulin de-
pendent, even after reduction of the tacrolimus dose. In our
study there was a significantly lower rate of patients requir-
ing antihypertensive therapy in the tacrolimus group, which
is similar to data obtained by Taylor and colleagues in
cardiac transplantation,19 whereas there was no significant
differences in terms of lipid disorders. Results of other
studies regarding hyperlipidemia and hypertension are con-
troversial.4,9,19,20 Therefore patients treated with tacrolimus
might have a lower cardiovascular risk unless they have
diabetes.21 The mechanisms for these differences are still
not clear. The rate of renal dysfunction was similarly low in
both groups and comparable with that seen in other studies.
Some transient phases of leukopenia were seen in both
patient groups, especially in the presence of ATG and
ganciclovir in the early postoperative course. Because the
latter 2 agents have known leukopenic effects, leukopenia
was not clearly attributable to MMF alone. In all patients,
MMF dosage was reduced, or the drug was temporarily
discontinued until leukocyte counts increased to normal
levels. In none of the patients did MMF have to be discon-
tinued permanently.
Summarizing this study, we show that both combinations
(CsA-MMF and tacrolimus-MMF) have a high immunosup-
pressive potency, which results in comparable low acute
rejection rates. Tacrolimus-MMF might be beneficial for
immunologically high-risk patients, who are more prone to
rejection episodes (ie, highly sensitized patients with posi-
tive cross-match) or for patients with a higher cardiovascu-
lar risk. On the other hand, CsA might be used preferentially
in diabetic patients or patients with a risk for diabetes (eg,
patients with cystic fibrosis).
At present, the question of which of these drug combi-
nations offers better immunosuppression can not be an-
swered and therefore must remain a center-specific decision.
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